NDLI: Delayed-onset neutropenia with divalproex sodium.

Please wait, while we are loading the content...

Year: 2017 Volume: 51

Year: 2016 Volume: 50

Year: 2015 Volume: 49

Year: 2014 Volume: 48

Year: 2013 Volume: 47

Year: 2012 Volume: 46

Year: 2011 Volume: 45

Year: 2010 Volume: 44

Year: 2009 Volume: 43

Year: 2008 Volume: 42

Year: 2008 Volume: 42 Issue: 12

Year: 2008 Volume: 42 Issue: 11

Year: 2008 Volume: 42 Issue: 10

Candesartan cilexetil effectively reduces blood pressure in hypertensive children.

Topiramate for alcohol dependence.

Delayed-onset neutropenia with divalproex sodium.

Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital.

Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.

Comparison of oral aspirin versus topical applied methyl salicylate for platelet inhibition.

Maribavir: a novel antiviral agent with activity against cytomegalovirus.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Desvenlafaxine: another 'me too' drug?

Posaconazole: an oral triazole with an extended spectrum of activity.

Dependence of time to reach steady-state on the length of dosage interval.

Assessing the reporting and scientific quality of meta-analyses of randomized controlled trials of treatments for anxiety disorders.

Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.

Sibutramine-associated QT interval prolongation and cardiac arrest.

Duloxetine-associated tachycardia.

Potential aluminum exposure from parenteral nutrition in patients with acute kidney injury.

Comment: Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?

Bevacizumab sterility in multiple doses from a single-use vial.

Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.

Medication reconciliation at hospital discharge: evaluating discrepancies.

Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.

Comment: Abacavir hypersensitivity reaction: an update.

Trastuzumab-induced hepatotoxicity.

Sustained-release fampridine for symptomatic treatment of multiple sclerosis.

Year: 2008 Volume: 42 Issue: 9

Year: 2008 Volume: 42 Issue: 7

Year: 2008 Volume: 42 Issue: 6

Year: 2008 Volume: 42 Issue: 5

Year: 2008 Volume: 42 Issue: 4

Year: 2008 Volume: 42 Issue: 3

Year: 2008 Volume: 42 Issue: 2

Year: 2007 Volume: 41

Year: 2003 Volume: 37

Delayed-onset neutropenia with divalproex sodium.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Stoner, Steven C. Deal, Eli Lurk, Jason T.
Description	Country affiliation: United States Author Affiliation: Stoner SC ( Division of Pharmacy Practice, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA. stoners@umkc.edu)
Abstract	OBJECTIVE: To report the development of neutropenia in a patient after almost 8 years of being stabilized on delayed-release divalproex sodium (DVPX). CASE SUMMARY: A 45-year-old man had been maintained on DVPX for nearly 8 years, with serum valproic acid concentrations of 85-128 mg/L and normal white blood cell (WBC) counts and absolute neutrophil counts (ANCs). Five months prior to the development of neutropenia (defined as ANC <1800 cells/microL), the patient's DVPX dosage was decreased by 250 mg to 1250 mg every morning and 1500 mg every evening. After 2 months of that regimen, the DVPX dosage was increased back to 1500 mg twice daily. Three months after that increase, the patient's WBC count dropped to 3.7 x 10(3)/microL and ANC was 1199 cells/microL. Although the ANC was below 1800 cells/microL, he showed no physical manifestations consistent with neutropenia. DVPX was discontinued, and 2 weeks later the patient's WBC count was 7.2 x 10(3)/microL and ANC was 2290 cells/microL. DISCUSSION: Although a complete blood cell count with differential is a commonly accepted form of therapeutic drug monitoring with DVPX, the monitoring is considered most necessary to identify dose-related thrombocytopenia. However, neutropenia has been rarely associated with the use of DVPX and could contribute to the development of different types of infection, including those of a bacterial, viral, or fungal origin. Although neutropenia is generally mild in severity, potentially severe DVPX-associated neutropenia can occur any time during the course of therapy, although it is most common within the first few months of treatment. In this case, DVPX was the probable cause of the neutropenia, according to the Naranjo probability scale. However, this case of neutropenia is atypical with respect to the timeframe in which it developed and was identified. Although the documented laboratory findings suggest neutropenia, the patient did not experience any clinical complications as a result. The late onset of the patient's neutropenia is unlike other cases that have been documented in the literature. CONCLUSIONS: Hematologic therapeutic drug monitoring continues to be clinically important regardless of whether the patient is early in therapy or even years later in the course. In this patient, continued regular therapeutic drug monitoring identified a suspected drug-related complication and the medication was able to be discontinued without the development of clinical complications.
File Format	HTM / HTML
ISSN	10600280
Issue Number	10
Volume Number	42
e-ISSN	15426270
Journal	Annals of Pharmacotherapy
Language	English
Publisher	SAGE Publications
Publisher Date	2008-10-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmaceutical Science Anticonvulsants Adverse Effects Neutropenia Chemically Induced Valproic Acid Administration & Dosage Pharmacokinetics Blood Cell Count Delayed-action Preparations Dose-response Relationship, Drug Drug Monitoring Humans Male Middle Aged Case Reports Journal Article
Content Type	Text
Resource Type	Case study Article
Subject	Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in